Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Subscribe To Our Newsletter & Stay Updated
